GlassScriptPhysician profile
Sandra M Henderson
NPI 1033664503
$2,311.45
in general payments reported to CMS, 2019-2025
18 companies · $565 in 2025
The $565 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $386 · 2022: $470 · 2023: $391 · 2024: $499 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $718.29 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $329.80 | 2022-2025 | Ilumya |
| Ucb, INC. | $230.28 | 2021-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $126.59 | 2021 | |
| Incyte Corporation | $126.43 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $120.23 | 2021-2025 | |
| Amgen INC. | $115.65 | 2023-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $84.93 | 2022-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $82.01 | 2023-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $73.65 | 2022-2024 | Vtama |
| Biofrontera INC. | $63.57 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $62.43 | 2023 | |
| Lilly USA, LLC | $52.47 | 2022-2024 | Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $34.83 | 2025 | Zoryve |
| Boston Scientific Corporation | $32.00 | 2022-2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $27.57 | 2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $17.19 | 2024 | Sotyktu |
| Organon LLC | $13.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.